TG Therapeutics Inc Cash Flow Conversion Efficiency
TG Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, TG Therapeutics Inc (TGTX) has a cash flow conversion efficiency ratio of 0.035x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($21.37 Million) by net assets ($604.08 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of TG Therapeutics Inc (1996–2025)
Cash flow conversion efficiency of TG Therapeutics Inc from 1996 to 2025. This chart illustrates how TG Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View TG Therapeutics Inc stock quote for real-time trading data and today's change.
TG Therapeutics Inc Cash Flow Conversion Ratio Explained
TG Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
TG Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TG Therapeutics Inc ranked by their cash flow conversion efficiency. Also see TG Therapeutics Inc (TGTX) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
360 Security Technology Inc
SHG:601360
|
-0.006x |
|
Jiangsu Yanghe Brewery Joint-Stock Co Ltd
SHE:002304
|
0.010x |
|
FirstCash Inc
NASDAQ:FCFS
|
0.076x |
|
Piraeus Financial Holdings S.A
AT:TPEIR
|
0.109x |
|
Blueprint Medicines Corp
NASDAQ:BPMC
|
-0.159x |
|
Restaurant Brands International Limited Partnership
TO:QSP-UN
|
0.043x |
|
Dundee Precious Metals Inc
TO:DPM
|
0.057x |
|
Redeia Corporacion S.A.
MC:RED
|
0.064x |
Annual Cash Flow Conversion Efficiency for TG Therapeutics Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of TG Therapeutics Inc from 1996 to 2025. Review TG Therapeutics Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $648.02 Million | $-24.77 Million | -0.038x | +79.02% |
| 2024-12-31 | $222.36 Million | $-40.52 Million | -0.182x | +6.90% |
| 2023-12-31 | $160.50 Million | $-31.41 Million | -0.196x | +93.49% |
| 2022-12-31 | $58.59 Million | $-176.17 Million | -3.007x | -141.22% |
| 2021-12-31 | $237.15 Million | $-295.63 Million | -1.247x | -201.82% |
| 2020-12-31 | $519.35 Million | $-214.51 Million | -0.413x | +87.99% |
| 2019-12-31 | $38.62 Million | $-132.81 Million | -3.439x | +35.88% |
| 2018-12-31 | $24.04 Million | $-128.93 Million | -5.364x | -- |
| 2017-12-31 | $0.00 | $-93.76 Million | x | -- |
| 2016-12-31 | $0.00 | $-61.59 Million | x | -- |
| 2015-12-31 | $0.00 | $-44.69 Million | x | -- |
| 2014-12-31 | $0.00 | $-35.06 Million | x | -- |
| 2013-12-31 | $0.00 | $-10.82 Million | x | -- |
| 2012-12-31 | $15.55 Million | $-5.19 Million | -0.334x | -3613.31% |
| 2011-12-31 | $9.64 Million | $-86.58K | -0.009x | -102.45% |
| 2010-12-31 | $-5.36 Million | $-1.97 Million | 0.367x | +137.37% |
| 2009-12-31 | $-6.78 Million | $-1.05 Million | 0.155x | -84.76% |
| 2008-12-31 | $-4.38 Million | $-4.44 Million | 1.016x | -91.15% |
| 2007-12-31 | $-891.09K | $-10.23 Million | 11.480x | +322.86% |
| 2006-12-31 | $1.50 Million | $-7.75 Million | -5.151x | -686.97% |
| 2005-12-31 | $9.54 Million | $-6.24 Million | -0.655x | +48.77% |
| 2004-12-31 | $4.45 Million | $-5.69 Million | -1.278x | -152.94% |
| 2003-12-31 | $6.83 Million | $-3.45 Million | -0.505x | -111.53% |
| 2002-12-31 | $-326.99K | $-1.43 Million | 4.381x | +222.37% |
| 2001-12-31 | $1.25 Million | $-4.47 Million | -3.580x | -240.33% |
| 2000-12-31 | $1.10 Million | $-1.15 Million | -1.052x | -55.51% |
| 1999-12-31 | $3.40 Million | $-2.30 Million | -0.676x | -53.51% |
| 1998-12-31 | $5.90 Million | $-2.60 Million | -0.441x | +9.71% |
| 1997-12-31 | $8.40 Million | $-4.10 Million | -0.488x | +74.37% |
| 1996-12-31 | $2.10 Million | $-4.00 Million | -1.905x | -- |
About TG Therapeutics Inc
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolat… Read more